Related references
Note: Only part of the references are listed.Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients
Sana Sara Dastgheyb et al.
BREAST (2023)
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
Jennifer R. Bellon et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Icro Meattini et al.
CANCER TREATMENT REVIEWS (2022)
Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2+breast cancer
Badr Id Said et al.
JOURNAL OF NEURO-ONCOLOGY (2022)
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database
Zhuo Ma et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2022)
In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells
F. Mignot et al.
CANCER RADIOTHERAPIE (2021)
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+breast cancer brain metastases
Matthew N. Mills et al.
BMC CANCER (2021)
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer
Icro Meattini et al.
LANCET ONCOLOGY (2021)
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
E. P. Mamounas et al.
ANNALS OF ONCOLOGY (2021)
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
F. Montemurro et al.
ANNALS OF ONCOLOGY (2020)
Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Eleonora Nicolo et al.
CURRENT OPINION IN ONCOLOGY (2020)
Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer Single-center Preliminary Results
Zita Zolcsak et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4
Priscilla K. Stumpf et al.
CLINICAL CANCER RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
Giuseppina Rosaria Rita Ricciardi et al.
BMC CANCER (2018)
Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer
Arthur Geraud et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review
Fabien Mignot et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
Vasileios Askoxylakis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
Vasileios Askoxylakis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases
Koichi Mitsuya et al.
BMC CANCER (2016)
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
William Jacot et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer
A. Geraud et al.
CANCER RADIOTHERAPIE (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
Stephen R. Adams et al.
NATURE COMMUNICATIONS (2016)
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo) Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Regional Nodal Irradiation in Early-Stage Breast Cancer
Timothy J. Whelan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET ONCOLOGY (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema
Julie A. Carlson et al.
NEURO-ONCOLOGY (2014)
Metaprop: a Stata command to perform meta-analysis of binomial data
Victoria N. Nyaga et al.
ARCHIVES OF PUBLIC HEALTH (2014)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer Clinical article
Douglas Kondziolka et al.
JOURNAL OF NEUROSURGERY (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial
LANCET (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells
H Asanuma et al.
CANCER RESEARCH (2005)
Stereotactic radiosurgery for multiple brain metastases from breast carcinoma - Feasibility and outcome of a local treatment concept
A Muacevic et al.
CANCER (2004)
Share Paper
